A Randomized Controlled Study of the Efficacy and Safety of a Bowel Preparation Regimen of 1L Polyethylene Glycol Combined with Lubiprostone Versus 2L Polyethylene Glycol

Start Date01 Nov 2024

Sponsor / Collaborator

The First Affiliated Hospital of Guangzhou Medical University

NCT06589154 / RecruitingNot ApplicableIIT

The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis

The application of multimodal data fusion in prostate cancer will bring new opportunities to improve diagnostic accuracy and treatment outcomes. By integrating imaging, genomics, pathology, and clinical data, we expect to realize precision medicine for prostate cancer and significantly improve the survival prognosis of patients.

Start Date10 Oct 2024

Sponsor / Collaborator

Shanghai Changzheng Hospital

[+4]

ChiCTR2400089972 / SuspendedPhase 4IIT

Two triple therapy on patients with newly dianosed type 2 diabetes: randomized, control study

Start Date08 Oct 2024

Sponsor / Collaborator

The First Affiliated Hospital of Guangzhou Medical University

100 Clinical Results associated with The First Affiliated Hospital of Guangzhou Medical University

0 Patents (Medical) associated with The First Affiliated Hospital of Guangzhou Medical University

4,565

Literatures (Medical) associated with The First Affiliated Hospital of Guangzhou Medical University

31 Dec 2024·Emerging Microbes & Infections

Establishment of a human organoid-based evaluation system for assessing interspecies infection risk of animal-borne coronaviruses

Article

Author: Han, Wei ; Zhou, Peng ; Yang, Xinglou ; Xie, Shizhe ; Wang, Qi ; Chen, Jing ; Gong, Qianchun ; Lin, Xinhua ; Jiang, Tingting ; Yang, Yong ; Wang, Xi ; Shi, Zhengli ; Lin, Haofeng ; Jiang, Rendi ; Ji, Lina ; Li, Qian ; Tang, Xiaofang ; Liu, Meiqin ; Guo, Zishuo

The COVID-19 pandemic presents a major threat to global public health. Several lines of evidence have shown that the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), along with two other highly pathogenic coronaviruses, SARS-CoV and Middle East Respiratory Syndrome (MERS-CoV) originated from bats. To prevent and control future coronavirus outbreaks, it is necessary to investigate the interspecies infection and pathogenicity risks of animal-related coronaviruses. Currently used infection models, including in vitro cell lines and in vivo animal models, fail to fully mimic the primary infection in human tissues. Here, we employed organoid technology as a promising new model for studying emerging pathogens and their pathogenic mechanisms. We investigated the key host-virus interaction patterns of five human coronaviruses (SARS-CoV-2 original strain, Omicron BA.1, MERS-CoV, HCoV-229E, and HCoV-OC43) in different human respiratory organoids. Five indicators, including cell tropism, invasion preference, replication activity, host response and virus-induced cell death, were developed to establish a comprehensive evaluation system to predict coronavirus interspecies infection and pathogenicity risks. Using this system, we further examined the pathogenicity and interspecies infection risks of three SARS-related coronaviruses (SARSr-CoV), including WIV1 and rRsSHC014S from bats, and MpCoV-GX from pangolins. Moreover, we found that cannabidiol, a non-psychoactive plant extract, exhibits significant inhibitory effects on various coronaviruses in human lung organoid. Cannabidiol significantly enhanced interferon-stimulated gene expression but reduced levels of inflammatory cytokines. In summary, our study established a reliable comprehensive evaluation system to analyse infection and pathogenicity patterns of zoonotic coronaviruses, which could aid in prevention and control of potentially emerging coronavirus diseases.

31 Dec 2024·Emerging Microbes & Infections

Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews

Article

Author: Wu, Weixuan ; He, Jun ; Li, Zhengfeng ; Zhang, Xiaoyan ; Liu, Yutong ; Qu, Linbing ; Feng, Ying ; Chen, Ling ; Zhou, Rong ; Li, Xiao ; Liu, Xinglong ; Sun, Xikui ; Ye, Xianmiao ; Wang, Nana ; Zhou, Zhichao ; Su, Wan ; Feng, Liqiang ; Zheng, Yali ; Liu, Wenkuan ; Wang, Wei

Re-emerging human adenovirus type 55 (HAdV55) has become a significant threat to public health due to its widespread circulation and the association with severe pneumonia, but an effective anti-HAdV55 agent remains unavailable. Herein, we report the generation of macaque-derived, human-like monoclonal antibodies (mAbs) protecting against HAdV55 infection with high potency. Using fluorophore-labelled HAdV55 virions as probes, we isolated specific memory B cells from rhesus macaques (Macaca mulatta) that were immunized twice with an experimental vaccine based on E1-, E3-deleted, replication-incompetent HAdV55. We cloned a total of 19 neutralizing mAbs, nine of which showed half-maximal inhibitory concentrations below 1.0 ng/ml. These mAbs recognized the hyper-variable-region (HVR) 1, 2, or 7 of viral hexon protein, or the fibre knob. In transgenic mice expressing human desmoglein-2, the major cellular receptor for HAdV55, a single intraperitoneal injection with hexon-targeting mAbs efficiently prevented HAdV55 infection, and mAb 29C12 showed protection at a dose as low as 0.004 mg/kg. Fibre-targeting mAb 28E8, however, showed protection only at a dose up to 12.5 mg/kg. In tree shrews that are permissive for HAdV55 infection and disease, mAb 29C12 effectively prevented HAdV55-caused pneumonia. Further analysis revealed that fibre-targeting mAbs blocked the attachment of HAdV55 to host cells, whereas hexon-targeting mAbs, regardless of their targeting HVRs, mainly functioned at post-attachment stage via inhibiting viral endosomal escape. Our results indicate that hexon-targeting mAbs have great anti-HAdV55 activities and warrant pre-clinical and clinical evaluation.

31 Dec 2024·Annals of Medicine

Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China

Article

Author: Xie, Jiaxing ; Li, You ; Cen, Xiaomin ; Deng, Zhenan ; Wen, Junjie ; Zhang, Qingling ; Ou, Changxing ; Liao, Yongkang

OBJECTIVEDupilumab has been approved for the treatment of severe asthma with type 2 inflammation by inhibiting interleukin (IL)-4 and IL-13 signaling. However, dupilumab-induced hypereosinophilia (HE) has been reported and should not be ignored. The aim of this study was to investigate the efficacy of dupilumab in Chinese patients with severe asthma, whether HE affects its efficacy, and the possible risk factors for HE.METHODS20 patients with severe asthma who received dupilumab treatment for at least 12 months in the First Affiliated Hospital of Guangzhou Medical University from 2019 to 2022 were included. We compared clinical data and laboratory tests results before dupilumab treatment and at 4 and 12 months after treatment. Based on whether dupilumab treatment triggers HE defined as blood eosinophil count (BEC) ≥ 1.5 × 10⁹ cells/L, the patients were allocated into non-HE and HE groups.RESULTSThe patients showed a significant increase in asthma control test (ACT) scores, a decrease in the number of exacerbations, a decrease in the proportion of patients taking an oral corticosteroid (OCS) and in the dose, and a significant improvement in the pulmonary function parameters FEV1/FVC (%) and FEV1 (% predicted) after 4 and 12 months of treatment with dupilumab. For type 2 inflammatory biomarkers, the levels of fractional concentration of exhaled nitric oxide (FeNO), sputum eosinophil count percentage (SEC%) and total immunoglobulin E (TIgE) decreased significantly, whereas BEC were higher after 4 months of treatment, but returned to baseline levels after 12 months. 8 patients (40%) developed asymptomatic HE after dupilumab, and the efficacy was not significantly different between the HE and non-HE groups. The earliest BEC elevation appeared at 1 month after treatment, but most of them declined after 6 months, and basically returned to the baseline level around 12 months of treatment. In addition, we further found that when patients had FeNO ≥ 60 ppb, food allergens positive and combined eosinophilic otitis media (EOM), their BEC increased significantly more than that of the control group after 4 months as well as 12 months of treatment.CONCLUSIONSThis study demonstrated that dupilumab was efficacious in Chinese patients with severe asthma, and some patients developed asymptomatic, self-limited HE, which did not affect its efficacy. Additionally, FeNO ≥60 ppb, food allergens positive, and co-morbidities with EOM may be the risk factors for developing HE.

100 Deals associated with The First Affiliated Hospital of Guangzhou Medical University

100 Translational Medicine associated with The First Affiliated Hospital of Guangzhou Medical University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ABOR-2013 ( EGFR )	Lung Cancer More	Phase 1
FLUCOV-10	COVID-19 More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis